


WHAT IS CLAIMED IS:

- 10010678-120701
- 5 1. A method of treating androgenic alopecia comprising administering to a person in need of such treatment a 5α -reductase 2 inhibitor in a dosage amount under 5.0 mgs/day.
 2. The method of Claim 1 wherein the dosage amount is from about 0.01 to 3.0 mgs/day.
 - 10 3. The method of Claim 1 wherein the dosage amount is from about 0.05 to 1.0 mg/day.
 4. The method of Claim 1 wherein the dosage amount is about 0.05 mg/day.
 - 15 5. The method of Claim 1 wherein the dosage amount is about 0.2 mgs/day.
 - 20 6. The method of Claim 1 wherein the androgenic alopecia is male pattern baldness.
 7. The method of Claim 1 wherein the 5α -reductase 2 inhibitor is administered orally.
 - 25 8. The method of Claim 1 wherein the 5α -reductase 2 inhibitor is administered topically.
 - 30 9. The method of Claim 1 wherein the 5α -reductase 2 inhibitor has the structural formula I



or a pharmaceutically acceptable salt thereof wherein:

R₁ is hydrogen, methyl or ethyl;


R₂ is a hydrocarbon radical selected from straight and branched chain alkyl of from 1-12 carbons or monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halogen (Cl, F or Br) substituents;

R' is hydrogen or methyl;

R'' is hydrogen or β -methyl; and

R''' is hydrogen, α -methyl or β -methyl.

10. The method of Claim 1 wherein the 5α -reductase 2 inhibitor has the structural formula II



or a pharmaceutically acceptable salt thereof wherein

R₁ is hydrogen, or methyl; and

R₃ is branched chain alkyl of from 4-8 carbons.

- 10010678-120704
- 5 11. A method of treating androgenic alopecia comprising administering to a person in need of such treatment 17β -(N-tert-butylcarbamoyl)-4-aza- 5α -androst-1-ene-3-one in a dosage amount under 5.0 mgs/day.
- 10 12. The method of Claim 11 wherein the androgenic alopecia is male pattern baldness.
13. The method of Claim 11 wherein the dosage amount is from about 0.01 to 3.0 mgs/day.
- 15 14. The method of Claim 11 wherein the dosage amount is from about 0.05 to 1.0 mg/day.
15. The method of Claim 11 wherein the dosage amount is about 0.05 mg/day.
- 20 16. The method of Claim 11 wherein the dosage amount is about 0.2 mg/day.
- 25 17. The method of Claim 11 wherein the 17β -(N-tert-butylcarbamoyl)-4-aza- 5α -androst-1-ene-3-one is administered topically.
18. The method of Claim 11 wherein the 17β -(N-tert-butylcarbamoyl)-4-aza- 5α -androst-1-ene-3-one is administered orally.
- 30 19. The method of Claim 18 wherein the dosage amount is about 0.2 mg/day.
20. The method of Claim 18 wherein the dosage amount is about 0.05 mg/day.

21. A method of arresting and reversing androgenic alopecia comprising administering to a person in need of such treatment a 5α -reductase 2 inhibitor in a dosage amount under 5.0 mgs/day.

5 22. A method of lowering the level of 5α -dihydrotestosterone in human scalp comprising administering to a person in need of such treatment a 5α -reductase 2 inhibitor in a dosage amount under 5.0 mgs/day.

10 23. The method of Claim 22 wherein the dosage amount is from about 0.01 to 3.0 mgs/day.

15 24. The method of Claim 22 wherein the dosage amount is from about 0.05 to 1.0 mg/day.

25 25. The method of Claim 22 wherein the dosage amount is about 0.05 mg/day.

20 26. The method of Claim 22 wherein the dosage amount is about 0.2 mg/day.

25 27. The method of Claim 22 wherein the dosage amount is about 1.0 mg/day.

25

30

10010678.120701